Why can't native human amylin be used as a medicine?

It aggregates into amyloid fibrils, and islet amyloid derived from it is a recognised feature of type 2 diabetes.

How does proline prevent aggregation?

Its ring removes the backbone amide hydrogen and constrains rotation, disrupting the regular hydrogen bonding a beta sheet requires.

Why attempt a human analogue rather than borrow rat residues?

Sequence changes can alter receptor engagement as well as aggregation, so retaining the human sequence avoids that trade.

GLP-1 & Incretin Science

The Amyloid Problem at the Centre of Amylin Design

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Human amylin aggregates into amyloid fibrils, which made the native peptide undeliverable. Every amylin-based medicine is therefore an engineering answer to that problem, and the two published answers take opposite approaches.

Key facts

Core problem: Human amylin forms amyloid fibrils
Pramlintide's solution: Three prolines from rat amylin
Why rat amylin: It does not aggregate
Petrelintide described as: Stable human amylin analogue
Second problem: Very short native half-life
Development paper: Fischer Munch 2025 (PMID 41217931)

Why amylin aggregates

Certain sequences are prone to stacking into ordered beta-sheet fibrils rather than remaining soluble. Human amylin is one, and islet amyloid deposits derived from it are a recognised feature of type 2 diabetes. A peptide whose natural tendency is to convert into insoluble fibrils cannot be formulated as a medicine without addressing that first.

Why proline is the classical fix

Proline's ring removes the backbone amide hydrogen and constrains rotation, which disrupts the regular hydrogen bonding a beta sheet requires. Inserting prolines is therefore a direct structural intervention against fibril formation — the residue physically cannot participate in the arrangement the aggregate needs.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The borrowed-sequence solution

Rat amylin does not aggregate, and the difference lies substantially in proline content. Pramlintide takes three positions from the rat sequence and puts them into the human one. It is an elegant solution because evolution had already produced a non-aggregating variant, and the design simply imported the relevant residues.

What a stable human analogue claims instead

Fischer Munch and colleagues describe petrelintide as a potent, stable, long-acting human amylin analogue. Retaining the human sequence while achieving stability is a harder engineering target than substituting rodent residues, and the reason to attempt it is that sequence changes can alter receptor engagement as well as aggregation behaviour.

The two problems are separate

Preventing aggregation and extending half-life are different engineering tasks with different solutions — structural disruption for the first, and typically some form of protraction such as lipidation or carrier binding for the second. A molecule solving both is solving two problems that could in principle be traded against each other.

Why this recurs across the catalogue

Aggregation is the failure mode running through several compounds on this site. IGF-1 LR3 aggregates when its fold is lost. Benzyl alcohol promotes aggregation of structured molecules. Amylin aggregates natively, without any provocation. Whether a molecule wants to stay soluble is a property of its sequence, and it determines what can be done with it.

Quick reference

	Pramlintide	Petrelintide
Approach to aggregation	Prolines from rat amylin	Stable human analogue
Sequence origin	Human with rodent substitutions	Human
Duration	Short — with meals	Long-acting
Status	Reached clinical use	Investigational

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why can't native human amylin be used as a medicine?: It aggregates into amyloid fibrils, and islet amyloid derived from it is a recognised feature of type 2 diabetes.
How does proline prevent aggregation?: Its ring removes the backbone amide hydrogen and constrains rotation, disrupting the regular hydrogen bonding a beta sheet requires.
Why attempt a human analogue rather than borrow rat residues?: Sequence changes can alter receptor engagement as well as aggregation, so retaining the human sequence avoids that trade.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum